Zhongsheng Pharmaceutical (002317.SZ) subsidiary RAY1225 project core patent authorized in Japan.

Chinastocks app news, Zhongsheng Pharmaceutical (002317.SZ) announced that its controlling subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. ("Zhongsheng Ruichuang") has recently received a patent certificate from the Japan Patent Office. The patent involves the preparation and application of peptides. This patent is a compound patent of the company's RAY1225 project, which is a core patent of the project. RAY1225 injection is a peptide drug with dual agonistic activity on GLP-1 receptor and GIP receptor. Thanks to its excellent pharmacokinetic properties, it has the potential to be a long-acting drug that can be injected every two weeks. Currently, RAY1225 injection is in phase III clinical trials, and the company will proceed with the project research and development as planned.